价值医疗时代的显微乳房再造:使用协同外科医生与降低成本、改善结局和增加价值相关
该回顾性研究纳入18个月内150例双侧显微乳房再造(60例单外科医生,90例外科医生/协同外科医生),中位随访15个月。倾向性评分匹配后,协同外科医生与平均手术时间缩短107分钟(p<0.001)和总成本降低1101.50美元(p<0.001)相关,团队频繁合作时更明显。协同外科医生对乳房部位并发症有保护作用,总体和重大并发症率有降低趋势。
要点
- 双侧显微乳房再造中,协同外科医生与手术时间缩短107分钟和成本降低1101.50美元相关。
- 外科医生/协同外科医生团队频繁合作时,手术时间缩短132分钟,成本降低1389美元(p=0.007)。
- 协同外科医生对乳房部位并发症有保护作用,总体和重大并发症率有降低趋势。
核心结论
- 使用协同外科医生的做法似乎与降低成本、改善结局相关,从而可能为双侧显微乳房再造增加价值。
研究设计与样本
- 回顾性综述了18个月期间所有接受双侧显微乳房再造的患者,分为单外科医生组和外科医生/协同外科医生组,共150例(60例单外科医生,90例外科医生/协同外科医生),中位随访15个月,采用倾向性评分控制基线特征,并建立局部加权逻辑回归模型分析协同外科医生对结局和成本的影响。
主要发现
- 匹配后,协同外科医生的存在与平均手术时间显著缩短相关(手术时间变化-107分钟;p<0.001)。
- 匹配后,协同外科医生的存在与总成本显著降低相关(总成本变化-1101.50美元;p<0.001)。
- 外科医生/协同外科医生团队频繁合作时,手术时间变化-132分钟,总成本变化-1389美元(p=0.007)。
- 加权逻辑回归模型发现,协同外科医生对乳房部位并发症有保护作用,并趋于降低总体和重大并发症率。
临床怎么用
- 作者认为,使用协同外科医生的做法似乎与降低成本、改善结局相关,从而可能为双侧显微乳房再造增加价值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Reducing complications while controlling costs is a central tenet of value-based health care. Bilateral microvascular breast reconstruction is a long operation with a relatively high complication rate. Using a two-surgeon team has been shown to improve safety in bilateral microvascular breast reconstruction; however, its impact on cost and efficiency has not been robustly studied. The authors hypothesized that a cosurgeon for bilateral microvascular breast reconstruction is safe, effective, and associated with reduced costs. METHODS: The authors retrospectively reviewed all patients who underwent bilateral microvascular breast reconstruction with either a single surgeon or surgeon/cosurgeon team over an 18-month period. Charges were converted to costs using the authors' institutional cost-to-charge ratio. Surgeon opportunity costs were estimated using time-driven activity-based costing. Propensity scoring controlled for baseline characteristics between the two groups. A locally weighted logistic regression model analyzed the cosurgeon's impact on outcomes and costs. RESULTS: The authors included 150 bilateral microvascular breast reconstructions (60 single-surgeon and 90 surgeon/cosurgeon reconstructions) with a median follow-up of 15 months. After matching, the presence of a cosurgeon was associated with a significantly reduced mean operative duration (change in operative duration, -107 minutes; p < 0.001) and cost (change in total cost, -$1101.50; p < 0.001), which was even more pronounced when surgeon/cosurgeon teams worked together frequently (change in operative duration, -132 minutes; change in total cost, -$1389; p = 0.007). The weighted logistic regression models identified that a cosurgeon was protective against breast-site complications and trended toward reduced overall and major complication rates. CONCLUSION: The practice of using a of cosurgeon appears to be associated with reduced costs and improved outcomes, thereby potentially adding value to bilateral microvascular breast reconstruction. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
引用
- Mericli AF, Chu CK, Sisk GC, et al. Microvascular Breast Reconstruction in the Era of Value-Based Care: Use of a Cosurgeon Is Associated with Reduced Costs, Improved Outcomes, and Added Value. Plast Reconstr Surg. 2022. PMID: 35077407. doi:10.1097/PRS.0000000000008715
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。